LC
VBIV

Lindbrook Capital’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Lindbrook Capital’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37
Closed -$2K – 2833
2022
Q1 		$2K Buy
+37
New +$1.83K ﹤0.01% 2121

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Lindbrook Capital's VBIV Position: Q2 2022 in Review

Lindbrook Capital sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2022, closing a stake of 37 shares — an estimated $2K sold.

Lindbrook Capital first reported a position in VBIV in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 130 funds tracked by Wall St. Rank hold VBIV as of Q2 2022.

  • Lindbrook Capital reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2022 after selling out during the quarter.
  • Lindbrook Capital sold 37 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2022, an estimated $2K.
  • Lindbrook Capital first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2022 and held it in 1 quarter.
  • Lindbrook Capital's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2K in Q1 2022.
  • 130 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2022.

Based on Lindbrook Capital's 13F filing for Q2 2022, filed 1 Aug 2022.